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Introduction 
Since 2001, the European Commission set a legislation defining maximum levels of polychlorinated dibenzo-p-
dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) in feed (and food) for 17 congeners1. Maximum 
level values for 12 additional congeners of dioxin-like polychlorinated biphenyls (DL-PCBs) have recently been 
added to the list and will enter in force soon (4th November 2006)2. 
The reference gas chromatography-isotope dilution high resolution mass spectrometry (GC-IDHRMS) 
methodology routinely allows the individual identification and quantification of these 29 congeners at the ultra-
trace level. Congener-specific data can be used as such for source tracking and identification or can be converted 
in toxic equivalent quantities (TEQs) based on the use of toxic equivalent factors (TEFs) to assess the overall 
toxicity3.  Because the high quality GC-IDHRMS monitoring of dioxins in the food chain is time and resource 
consuming, alternative sample screening methods are needed. The DR-CALUX (Dioxin Response-Chemically 
Activated LUciferase gene eXpression) cell-based assay has widely been proposed to screen dioxin and dioxin-
like compounds in food and feed samples. Compared to congener-specific GC-IDHRMS data, the CALUX AhR 
(Aryl hydrocarbon receptor)-activation mediated response directly yield to a TEQ estimation based on a 
correlation with 2,3,7,8-TeCDD induction of the assay. 
A comparison between GC-IDHRMS and DR-CALUX results often shows discrepancies, partly due to 
differences between the WHO-TEF values and the CALUX REP (relative equivalent potency) values4,5 measured 
for each of the PCDD, PCDF and DL-PCB congeners. In addition, although analyte recovery rates are taken into 
account for calculations in GC-IDHRMS, no correction for analytes loss based on internal standards is possible in 
a cell based assay. 
Such differences make difficult the strict decision of compliance or suspicion of non compliance for samples 
submitted to biological screening. Another difficulty of the screening stage is to determine a limit of decision, 
allowing “to select those samples with levels of dioxins and DL-PCBs that are less than 30-40% below or exceed 
the level of interest”6 but yielding to a rate of false negative decision lower than 1%6.  Furthermore, the rate of 
false positive decision should be very low to ensure profitable use of the screening procedure (all samples 
suspected to be positive at the screening stage have to be tested by a confirmatory method, i.e., the GC-IDHRMS). 
We show and evaluate here a DR-CALUX screening strategy for dioxin monitoring in feed samples, allowing 
correction of DR-CALUX raw data and a rate of false negative les than 1%. The level of contamination with 
PCDD/F and DL-PCB congeners of a large number of feed samples analyzed routinely by GC-IDHRMS is also 
presented. 
 
Materials and methods 
Samples are unknown samples issued from the routine monitoring activity (with GC-IDHRMS) of the laboratory 
of mass spectrometry. QC samples and method blanks (BCs) were regularly run for QA/QC purposes. 
Extraction: For GC-IDHRMS analyses of PCDD/Fs and dioxin-like PCBs, samples were extracted and cleaned-
up as already described7. For DR-CALUX analyses, samples were liquid-liquid (LLE) extracted and cleaned-up 
according to the method proposed by the manufacturer.  
Analysis : GC-IDHRMS analysis of PCDD/Fs and DL-PCBs were performed as already described7. DR-CALUX 
originates from BioDetection System (BDS, NL). Briefly, samples extracts were cleaned-up manually using liquid 
chromatography on acidic silica columns. Final extracts were concentrated in DMSO prior to analysis. All details 
are available elsewhere4. 
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> 1.25 pg PCDD/Fs + DL-PCBs WHO-TEQ/g
 
Figure 1 : Distribution of results obtained from the monitoring of 116 feed 
samples (GC-IDHRMS method). 
 
Figure 1 shows results of dioxin (17 PCDD/Fs and 12 DL-PCBs) monitoring 
of 116 feed samples classified as “Feed materials of plant origin with the 
exception of vegetable oils and their by products”1,2. For these samples, 
PCDD/Fs and total (PCDD/Fs + DL-PCBs) WHO-TEQ maximal levels are 
respectively 0.75 and 1.25 pg/g, while separate action levels exist for 
PCDD/Fs and DL-PCBs2, which 
are respectively 0.5 and 0.35 pg 
WHO-TEQ/g.   
113 samples (97%) were below 
the maximum level for dioxins 
and furans, from which only two 
displayed levels above the 
maximum level for the sum of 
dioxins, furans and DL-PCBs.  
From these 113 samples, 4 are 
above the PCDD/Fs action level 
and one is below the PCDD/Fs 
action level and slightly above 
the DL-PCBs action level. Only 
3 samples (3%) were above both 
dioxin/furans and total 
maximum limits, but with a DL-
PCBs contamination close to or 
below their action level.  
 
DR-CALUX screening strategy 
Correction of raw data 
Usually, when comparing total TEQ levels (dioxins, furans and DL-PCBs) obtained for the same samples, 
CALUX measurements are lower than GC-IDHRMS. The main reason of this is that REP for DL-PCBs are lower 
than WHO-TEF4,5. Other causes such as loss of analytes during extraction and purification and antagonistic effects 
of some PCBs congeners can be mentioned. 
As shown in a previous project (DIFFERENCE)8, the use of reference samples to correct DR-CALUX results 
show a good improvement in the comparison of GC-IDHRMS and DR-CALUX measurement but, unfortunately, 
these kind of samples are not commercially available. 
 
Compounds WHO-TEF DR-CALUX REP4 pg/g




2,3,7,8-TCDD 1 1 0.011 0.0110 0.0110
1,2,3,7,8-PeCDD 1 0.5 0.04 0.0400 0.0200
1,2,3,4,7,8-HxCDD 0.1 0.1 0.16 0.0160 0.0160
1,2,3,6,7,8-HxCDD 0.1 0.06 1.985 0.1985 0.1191
1,2,3,7,8,9-HxCDD 0.1 0.05 0.779 0.0779 0.0390
1,2,3,4,6,7,8-HpCDD 0.01 0.03 146.286 1.4629 4.3886
1,2,3,4,6,7,8,9-OCDD 0.0001 0.0005 742.237 0.0742 0.3711
2,3,7,8-TCDF 0.1 0.4 0.092 0.0092 0.0368
1,2,3,7,8-PeCDF 0.05 0.1 0.029 0.0015 0.0029
2,3,4,7,8-PeCDF 0.5 0.4 0.051 0.0255 0.0204
1,2,3,4,7,8-HxCDF 0.1 0.07 0.073 0.0073 0.0051
1,2,3,6,7,8-HxCDF 0.1 0.08 0.044 0.0044 0.0035
2,3,4,6,7,8-HxCDF 0.1 0.1 0.049 0.0049 0.0049
1,2,3,7,8,9-HxCDF 0.1 0.1 0.0000 0.0000
1,2,3,4,6,7,8-HpCDF 0.01 0.01 1.582 0.0158 0.0158
1,2,3,4,7,8,9-HpCDF 0.01 0.04 0.195 0.0020 0.0078
1,2,3,4,6,7,8,9-OCDF 0.0001 0.004 13.129 0.0013 0.0525
TOTAL PCDD/Fs 907 1.95 5.11        
PCB 77 0.0001 0.0004 7.33 0.0007 0.0029
PCB 126 0.1 0.04 0.45 0.0446 0.0178
PCB 169 0.01 0.0008 0.08 0.0008 0.0001
PCB 81 0.0001 0.002 0.43 0.0000 0.0009
PCB 105 0.0001 0 28.64 0.0029 0.0000
PCB 114 0.0005 0.00002 2.36 0.0012 0.0000
PCB 118 0.0001 0 93.68 0.0094 0.0000
PCB 123 0.0001 0 2.72 0.0003 0.0000
PCB 156 0.0005 0.00002 12.51 0.0063 0.0003
PCB 157 0.0005 0 2.16 0.0011 0.0000
PCB 167 0.00001 0 6.76 0.0001 0.0000
PCB 189 0.0001 0 1.42 0.0001 0.0000
TOTAL dioxin-like PCBs 159 0.1 0.02
TOTAL 1065 2.0 5.14  
Table I : GC-IDHRMS results of the “home made” feed QC sample.  
 
We propose here to correct DR-CALUX 
data using a “home made” quality 
control (QC) sample. That QC sample, 
which is a real contaminated feed 
material, previously used in an 
interlaboratory study10, is incorporated 
in the series of unknown samples and 
analyzed accordingly. The GC-
IDHRMS analysis of this samples 
showed a very high contamination with 
the 1,2,3,4,6,7,8-HpCDD congener, 
which displays a DR-CALUX REP 3 
fold higher than its WHO-TEF (0.03 and 
0.01 respectively) (table 1). The DR-
CALUX measurement of this sample 
shows a level of 3.7 pg total TEQ/g, 
which is higher than the GC- 
IDHRMS measurement (2.0 pg total 
TEQ/g). This difference comes from the 
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When using DR-CALUX REP instead of WHO-TEF to calculate the TEQ content, we find a calculated 
concentration of 5.1 pg calculated “DR-CALUX TEQ”/g (last column of Table 1). 
This concentration is our reference concentration for the DR-CALUX measurement. The average DR-CALUX 
response found during the validation of the method was 72% of that DR-CALUX reference concentration (3.7 pg 
TEQ/g measured with DR-CALUX versus 5.1 pg “REP-calculated” TEQ/g). The resulting average multiplicative 
correction factor is 1.4.  Because this QC contains very low levels of DL-PCBs, it allows correction of unknowns 
for recovery (analyte loss during extraction and purification steps) assuming that it is roughly the same for all 
congeners.  Practically, the DR-CALUX result found for the unknown is multiplied by the correction factor, 
calculated from the result obtained for the QC sample analyzed in the same series than the unknown. 
 
Limit of decision at the DR-CALUX screening stage 
To calculate a CALUX decision limit allowing meeting the criteria of less than 1% of false negative set for 
screening techniques7, we used a statistical approach. To determine the rate of false negative samples (true 
positive samples declared negative at the screening stage), we have first to define the limit at which a sample is 
declared positive. The non-compliance of a sample (true positive sample) is only declared at the confirmatory step 
(GC-IDHRMS) if its concentration is above the maximal limit taking into account the measurement uncertainty10 
(what we call here the GC-IDHRMS decision limit).  Until now, regulatory limits exist for the TEQ concentration 
of PCDD/F congeners only (no DL-PCBs included).  By November 4th 2006, regulatory limits for total (PCDD/Fs 
and DL-PCBs) TEQ concentrations will enter into force, but PCDD/Fs TEQ maximum limits will still be 













Figure 2 : Distribution of the contamination measurement of a 
population of positives samples containing a PCDD/F WHO-TEQ 
corresponding to the GC-IDHRMS decision limit (i.e. the PCDD/F WHO-
TEQ maximal level + the measurement uncertainity). DL : Decision limit. 
σ : standard deviation of the mean of the CALUX measurements 
calculated with a CV of 25%. β : beta error, percentage of positive 
samples below the CALUX decision limit (rate of false negative samples).  
 
For that reason, and to reduce the false negative rate as much as possible, 
we choose to calculate a CALUX decision limit that takes into account 
the lowest maximum limit (e.g. which is the PCDD/Fs TEQ maximum 
limit). In Figure 2, the dotted distribution corresponds to the expected 
GC-IDHRMS results for a population of positive samples, contaminated 
with a PCDD/F WHO-TEQ 
corresponding to the maximum legal 
limit plus the expanded uncertainty 
(we consider that an average 
expanded uncertainty of 20% is 
associated to a GC-IDHRMS 
measurement). The plain line 
distribution represents the expected 
DR-CALUX measurements for the 
same samples. In order to obtain 
less than 1% of false negative 
decision (which corresponds to the 
beta error) at the screening stage, 
the DR-CALUX decision limit is 
calculated as the inferior limit of the 
99% unilateral confidence interval 
of a population of results 
characterized by a mean being equal 
to the GC-IDHRMS decision limit 
and a coefficient of variation (CV) 
of 25%, which is an average 
reproducibility CV of the DR-
CALUX analysis (Figure 2). This 
CALUX decision limit has been 
calculated assuming that the 
recovery of the DR-CALUX method 
is 100 % (after correction). 
 
Evaluation of the DR-CALUX screening  
Table 3 shows results obtained with both DR-CALUX and GC-IDHRMS methods when analyzing real feed 
samples.  From the 26 samples analyzed, only 3 are above the GC-IDHRMS decision limit for the PCDD/Fs TEQ 
content. As mentioned in the European Legislation, the screening has to detect samples 30% to 40% below the 
maximal level, so we evaluated the CALUX screening decision by comparing the number of samples above the 
DR-CALUX decision limit to the number of samples above 60% of the regulatory limit. Ten samples are above 
60% of both the PCDD/Fs and the total (PCDD/Fs + DL-PCBs) WHO-TEQ maximum limits, all detected with the 
DR-CALUX screening, and 2 samples are above the total TEQ maximal limit only, also detected with the DR-
CALUX screening.  From the 15 remaining negative samples, four are detected as suspicious after the DR-
CALUX screening and are thus false positive.   
2.33 * σ 
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(HRMS) > maximal 
level - 40% ?
PCDD/F + PCB WHO-
TEQ (HRMS) > 




1 0.19 - 0.11 0.23 - - TRUE
2 0.19 - 0.11 0.23 - - TRUE
3 0.19 - 0.11 0.22 - - TRUE
4 0.19 - 0.11 0.22 - - TRUE
5 0.19 - 0.11 0.22 - - TRUE
6 0.19 - 0.11 0.22 - - TRUE
7 0.19 - 0.11 0.28 - - TRUE
8 0.19 - 0.11 0.22 - - TRUE
9 0.19 - 0.11 0.23 - - TRUE
10 0.50 + 0.11 0.23 - - FALSE
11 0.19 - 0.11 0.23 - - TRUE
12 0.75 + 0.12 0.25 - - FALSE
13 0.19 - 0.13 0.23 - - TRUE
14 0.46 + 0.20 0.36 - - FALSE
15 1.42 + 0.21 0.40 - - FALSE
16 0.51 + 0.37 0.91 - + TRUE
17 0.94 + 0.44 0.86 - + TRUE
18 1.67 + 0.46 1.23 + + TRUE
19 0.44 + 0.64 0.64 + - TRUE
20 2.24 + 0.67 0.79 + + TRUE
21 1.73 + 0.70 1.42 + + TRUE
22 0.65 + 0.71 0.84 + + TRUE
23 1.05 + 0.72 0.84 + + TRUE
24 2.45 + 0.95 1.07 + + TRUE
25 13.34 + 5.64 5.76 + + TRUE
26 5.10 + 6.42 6.55 + + TRUE  
Table 3 : DR-CALUX (pg DR-CALUX TEQ/g product, QC corrected) and GC-IDHRMS (HRMS) results of the 
analysis of 26 feed samples. The DR-CALUX screening conclusion is + if the DR-CALUX measured level is above 
the DR-CALUX decision limit. 
 
Conclusions 
We have developed a strategy to screen feed samples with the DR-CALUX cell-based assay, with a rate of less 
than 1% of false negative decisions and a “home made” QC sample to correct for recovery.  Even if this QC 
sample does not allow a correction for the difference between REP and TEF, it seems to work well to detect those 
samples containing a high level of DL-PCBs (samples 16 to 26 of Table 3).  
We can conclude that the strategy shown here is good to screen samples in a situation of routine monitoring where 
a high rate of samples (more than 90%) are negative (compliant with both PCDD/Fs and total (PCDD/Fs + DL-
PCBs) WHO-TEQ maximum levels) and a very low rate are non compliant to the total WHO-TEQ maximum 
level while compliant to the PCDD/Fs one. The congener profile found in the compliant samples corresponds to 
the background contamination. 
On the contrary, in a crisis situation, the congener pattern found in samples depends of the origin of the 
contamination (such as for example in the Belgian dioxin crisis in feed at the begin of 2006, where feed was 
contaminated with specific congeners). It would be then interesting to prepare a dedicated reference sample 
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